Population pharmacokinetics I: background, concepts, and models
- PMID: 15328391
- DOI: 10.1345/aph.1D374
Population pharmacokinetics I: background, concepts, and models
Abstract
Objective: To present and emphasize the background, foundations, utility, and conceptual underlying theory of the population pharmacokinetic (PPK) approach with an examination of the advantages when compared with other approaches of pharmacokinetic modeling.
Data sources: Information on PPK was retrieved from a MEDLINE search (1979-June 2002) of literature and a bibliographic review of review articles and books.
Study selection and data extraction: All articles identified from data sources were evaluated and relevant information was included in this review.
Data synthesis: PPK plays a pivotal role in developing dosing strategies for direct patient care and in drug development. PPK is valuable because it targets the patient group that will eventually receive the drug of interest, quantitates pharmacokinetic variability at several levels, and seeks to explain those sources of variability.
Conclusions: PPK models have great utility and the applications are many. They are very different from single-subject pharmacokinetic models and therefore require different approaches to model development.
Similar articles
-
Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.Ann Pharmacother. 2004 Dec;38(12):2136-44. doi: 10.1345/aph.1E260. Epub 2004 Oct 26. Ann Pharmacother. 2004. PMID: 15507495 Review.
-
Population pharmacokinetics II: estimation methods.Ann Pharmacother. 2004 Nov;38(11):1907-15. doi: 10.1345/aph.1E259. Epub 2004 Sep 14. Ann Pharmacother. 2004. PMID: 15367729 Review.
-
Model appropriateness and population pharmacokinetic modeling.J Clin Pharmacol. 2003 Jun;43(6):610-23. J Clin Pharmacol. 2003. PMID: 12817524
-
Physiologically based pharmacokinetics (PBPK).Drug Metab Rev. 2009;41(3):391-407. doi: 10.1080/10837450902891360. Drug Metab Rev. 2009. PMID: 19601719 Review.
-
Basic principles and techniques of pharmacokinetic modeling.J Zoo Wildl Med. 1997 Mar;28(1):3-19. J Zoo Wildl Med. 1997. PMID: 9226611 Review.
Cited by
-
Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome.Br J Clin Pharmacol. 2015 Aug;80(2):242-52. doi: 10.1111/bcp.12607. Epub 2015 Jun 5. Br J Clin Pharmacol. 2015. PMID: 25677380 Free PMC article.
-
Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models.AAPS J. 2012 Sep;14(3):420-32. doi: 10.1208/s12248-012-9349-2. Epub 2012 Apr 14. AAPS J. 2012. PMID: 22528503 Free PMC article.
-
Population Pharmacokinetic Models of Vancomycin in Paediatric Patients: A Systematic Review.Clin Pharmacokinet. 2021 Aug;60(8):985-1001. doi: 10.1007/s40262-021-01027-9. Epub 2021 May 18. Clin Pharmacokinet. 2021. PMID: 34002357
-
Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients.J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):427-438. doi: 10.1007/s10928-019-09637-4. Epub 2019 May 21. J Pharmacokinet Pharmacodyn. 2019. PMID: 31115857 Free PMC article.
-
An In Silico Approach toward the Appropriate Absorption Rate Metric in Bioequivalence.Pharmaceuticals (Basel). 2023 May 10;16(5):725. doi: 10.3390/ph16050725. Pharmaceuticals (Basel). 2023. PMID: 37242508 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources